10x Genomics, Inc.

TXG

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001610717-26-000086
Filing date: Mar 4, 2026
Earliest execution date: Mar 2, 2026
Reporting Owners: Saxonov Serge (CEO)

Summary

Type

Sell

Net shares

-18,902

% of shares

-1.27%

Amount (USD)

$367,096

Insider confidence score

45.0 out of 100

Positive

  • Under Rule 10b5-1 trading plan

Negative

  • Moderate scheduled sell (<2% of shares)
  • Large sell amount ($250K+)

Stock transactions

Transaction 1

Security

Class A Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-14,292.0

Price per Share

$22.67

Amount (USD)

$323,985.35

Acquired/Disposed

Disposed

Shares Owned Before

1,219,819.0

Shares Owned After

1,205,527.0

Transaction 2

Security

Class A Common Stock

Action

Sell

Date

2026-03-02

Code

S

Net shares

-1,860.0

Price per Share

$23.18

Amount (USD)

$43,111.27

Acquired/Disposed

Disposed

Shares Owned Before

1,205,527.0

Shares Owned After

1,203,667.0

Transaction 3

Security

Class A Common Stock

Action

Grant

Date

2026-03-03

Code

G

Net shares

-2,750.0

Acquired/Disposed

Disposed

Shares Owned Before

1,203,667.0

Shares Owned After

1,200,917.0

Filing's footnotes

1. The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

2. This transaction was executed in multiple trades at prices ranging from $22.15 to $23.145, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. This transaction was executed in multiple trades at prices ranging from $23.15 to $23.25, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

5. The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

6. The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.

ℹ️ Filed under Rule 10b5-1 trading plan

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.